Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
212 patients were included (180 male and 142 patients < 60 years old).
I · Intervention 중재 / 시술
radical liver resection between January 2017 and December 2020
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our findings suggest that assessing LVD in the tumor capsule could serve as a useful tool in predicting postoperative prognosis and guiding personalized treatment strategies for patients with early-stage HCC.
[OBJECTIVE] Lymphatic vessels are present in the capsule of hepatocellular carcinoma (HCC) at an early stage, but their value in the prognosis remains unclear.
- 95% CI 1.096-4.197
- OR 8.493
- HR 2.145
APA
Li J, Liang YB, et al. (2026). Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk.. Frontiers in immunology, 17, 1714314. https://doi.org/10.3389/fimmu.2026.1714314
MLA
Li J, et al.. "Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk.." Frontiers in immunology, vol. 17, 2026, pp. 1714314.
PMID
41685307 ↗
Abstract 한글 요약
[OBJECTIVE] Lymphatic vessels are present in the capsule of hepatocellular carcinoma (HCC) at an early stage, but their value in the prognosis remains unclear. The study aimed to evaluate the prognostic impact of lymphatic vessels in the tumor capsule on patients with HCC at Barcelona Clinic Liver Cancer (BCLC) stages 0-A. This is one of the first studies to investigate the tumor capsule specifically.
[METHODS] This retrospective study included HCC patients at BCLC stages 0-A, who underwent radical liver resection between January 2017 and December 2020. Lymphatic vessel density (LVD) in the tumor capsule was determined by immunohistochemistry using anti-D2-40. Patients were stratified into the high and low LVD groups. Their overall survival (OS) and recurrence-free survival (RFS) were analyzed. The potential risk factors affecting survival and for predicting microvascular invasion (MVI) or satellite nodules were analyzed using Cox regression analysis and logistic regression analysis, respectively.
[RESULTS] A total of 212 patients were included (180 male and 142 patients < 60 years old). The 1, 3, and 5-year OS were 76.5%, 52.9%, and 41.2% in the high LVD group, versus 94.4%, 76.4%, and 69.0% in the low LVD group ( = 0.013). The 1, 3, and 5-year RFS were 30.6%, 30.6%, and 30.6% in the high LVD group, versus 72.5%, 52.2%, and 38.7% in the low LVD group ( = 0.014). High LVD in the tumor capsule was an independent risk factor for worse OS (HR = 2.145, 95% CI: 1.096-4.197, = 0.026) and RFS (HR = 2.506, 95% CI: 1.197-5.243, = 0.015), and also associated with the onset of MVI (OR = 8.493, 95% CI: 2.314-31.174, = 0.001) and satellite nodules (OR = 5.755, 95% CI: 1.340-24.718, = 0.019).
[CONCLUSIONS] High LVD in the tumor capsule was associated with worse OS, RFS, and intrahepatic spread (MVI and satellite nodules) in patients with HCC at BCLC stages 0-A after liver resection. Our findings suggest that assessing LVD in the tumor capsule could serve as a useful tool in predicting postoperative prognosis and guiding personalized treatment strategies for patients with early-stage HCC.
[METHODS] This retrospective study included HCC patients at BCLC stages 0-A, who underwent radical liver resection between January 2017 and December 2020. Lymphatic vessel density (LVD) in the tumor capsule was determined by immunohistochemistry using anti-D2-40. Patients were stratified into the high and low LVD groups. Their overall survival (OS) and recurrence-free survival (RFS) were analyzed. The potential risk factors affecting survival and for predicting microvascular invasion (MVI) or satellite nodules were analyzed using Cox regression analysis and logistic regression analysis, respectively.
[RESULTS] A total of 212 patients were included (180 male and 142 patients < 60 years old). The 1, 3, and 5-year OS were 76.5%, 52.9%, and 41.2% in the high LVD group, versus 94.4%, 76.4%, and 69.0% in the low LVD group ( = 0.013). The 1, 3, and 5-year RFS were 30.6%, 30.6%, and 30.6% in the high LVD group, versus 72.5%, 52.2%, and 38.7% in the low LVD group ( = 0.014). High LVD in the tumor capsule was an independent risk factor for worse OS (HR = 2.145, 95% CI: 1.096-4.197, = 0.026) and RFS (HR = 2.506, 95% CI: 1.197-5.243, = 0.015), and also associated with the onset of MVI (OR = 8.493, 95% CI: 2.314-31.174, = 0.001) and satellite nodules (OR = 5.755, 95% CI: 1.340-24.718, = 0.019).
[CONCLUSIONS] High LVD in the tumor capsule was associated with worse OS, RFS, and intrahepatic spread (MVI and satellite nodules) in patients with HCC at BCLC stages 0-A after liver resection. Our findings suggest that assessing LVD in the tumor capsule could serve as a useful tool in predicting postoperative prognosis and guiding personalized treatment strategies for patients with early-stage HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Ultrasound guided transabdominal botulinum toxin injection for refractory overactive bladder treatment.
- Short Nose Lengthening in Primary and Revision Rhinoplasty in Asians.
- Histopathological changes of fibrosis in human extra-ocular muscle caused by botulinum toxin A.
- Corrigendum to "Dual-energy CT radiomics for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer: A dual-vendor validation study" [Eur. J. Surg. Oncol. 51 (2025) 110548].
- A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis.